Establishment of Taxol-resistance ovarian carcinoma cell line OV1228/Taxol

Chinese Journal of Cancer Prevention and Treatment

Volumn 17, Issue 23, 2010, Pages 1920-1923

  Wang, Jin Hua ^a   Zhao, Wan Zhou ^a   Chen, Xiao Xiang ^a   Zhao, Yi Bing ^a   Qu, Jun Wei ^a   Peng, Su Rong ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Cell line; Drug tplerance; Ovarian neoplasms; Paclitaxel

Indexed keywords

CISPLATIN; FLUOROURACIL; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN KINASE C ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE; CELL POPULATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GROWTH CURVE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 79955936500     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Nardi M, De-Marco S, Fabi A, et al. Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer[J]. CCP, 2001,48(3):255-258. (Pubitemid 32758902)
2. Li F, Ambrosini G, Chu E Y, et al. Control of apoptosis and mitotic spindle checkpoint by surviving[J]. Nature, 1998,396(2):580-583.
3. Yu G, Ahmad S, Aquino A, et al. Transfection with protein kinase C-α confers increased multidrug resistance to MCF27 cells expressing P-glyco-protein[J]. Cancer Commun, 1991,3:181-189.
4. Gill P K, Gescher A, Gant T W. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta[J]. Eur J Biochem, 2001,268(15):4151-4157. (Pubitemid 32862875)
5. Li L, Luan Y, Wang G, et al. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma[J]. Int J Mol Med, 2004,14(2):257-264.